Navigation Links
Sinovac's CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
Date:12/28/2009

ac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccine.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

     Investors:
     Amy Glynn/Stephanie 
'/>"/>
SOURCE  Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 

Related biology technology :

1. Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
3. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
4. Additional Data From Fidaxomicins Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
5. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
6. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
7. Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO/ESMO on September 22, 2009
8. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting
9. Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting
10. Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
11. $10,000 ISSAC Award for Innovation Presented to MIT PhD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Ras Al Khaimah, UAE (PRWEB) May 21, 2013 ... and private equity consultancy specializing in “game-changing” life science ... appointment of Ms. Dalia Dergham to its International Project ... certain to bring even greater multi-cultural depth to Grace ... more projects around the globe. , Ms. Dergham holds ...
(Date:5/20/2013)... , May 20, 2013 Today, at the ... Francisco , James McGough , ... at the Semel Institute for Neuroscience and Human Behavior ... Medicine at the University of California Los Angeles (UCLA), ... and Adolescent Psychopharmacology and ADHD at UCLA, presented the ...
(Date:5/20/2013)... SEATTLE , May 20, 2013 Pacific Biomarkers ... laboratory solutions for developers of biosimilars at the ... the Sheraton San Diego Hotel and Marina ... Attendees will have the opportunity to speak with company ... Development: Paths That Cross" on May 21 from 1-2 ...
(Date:5/20/2013)... HILL, N.C. , May 20, 2013 /PRNewswire/ ... company focused on developing differentiated antibiotics to meet ... infections, today announced that it presented data at ... in Philadelphia demonstrating the ... levofloxacin in Cempra,s prior Phase 2 clinical trial ...
Breaking Biology Technology:Dalia Dergham Joins Grace Century FZ LLC International Project Team 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2
... which has promised Milwaukee that it can provide citywide wireless ... by the Milwaukee Common Council after falling behind ... Midwest Fiber until June 7 to hook up the first ... company was to have the area hooked up by mid-January, ...
... voiced across the state that the recent U.S. Patent ... the patenting and licensing arm of the University of ... acknowledged leadership in stem cell research. , ,As one of ... overreaching patents on human embryonic stem cells held by the ...
... Is America rushing into the adoption of electronic medical ... data security? , ,The question has been raised on ... to provide incentives to encourage the adoption of interactive ... are construed as a barrier to the adoption of ...
Cached Biology Technology:Patent ruling doesn't tarnish Wisconsin's stem cell leadership 2Patent ruling doesn't tarnish Wisconsin's stem cell leadership 3Privacy, trust still the biggest barriers to electronic record sharing 2Privacy, trust still the biggest barriers to electronic record sharing 3
(Date:5/17/2013)... Why Tibetan antelope can live at elevations of ... research published in Nature Communications , investigators ... evidence that some genetic factors may be associated ... The data in this work will also provide ... biology of other ruminant species. , The Tibetan ...
(Date:5/16/2013)... a commitment to the support of underrepresented minority ... Foundation has announced the inaugural AGA Investing in ... by the National Institute of Diabetes and Digestive ... underrepresented minority students to further their research careers ... establishing this new award, AGA demonstrates its commitment ...
(Date:5/16/2013)... in neurodegenerative disease also plays a critical role in ... In a study of the common fruit fly, the ... responsible for sleeping and waking on a 24-hour rhythm. ... sleep-wake cycle is disturbed, making waking up on a ... discovery is particularly interesting because mutations in the human ...
Breaking Biology News(10 mins):The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2Gene involved in neurodegeneration keeps clock running 2
... global studies of future species shifts and losses foresees ... but offers new hope that it could be slowed ... experts Henrique Miguel Pereira and Paul Leadley, the 23-member ... DIVERSITAS, UNEP-WCMC and the secretariat of the CBD compared ...
... Spanish . , Scientists with the U.S. Department ... that,s always a hit at festive gatherings also is always ... a first-of-its-kind mathematical model that food processors and others can ... of salt and smoke compounds to reduce or eliminate microbial ...
... Asian-American youth are one of the fastest growing populations ... later in life, they are more likely to smoke ... or racial groups, according to the Department of Health ... is examining the unique differences in adolescent tobacco use ...
Cached Biology News:Continuing biodiversity loss predicted but could be slowed 2Continuing biodiversity loss predicted but could be slowed 3USDA scientists helping keep in-demand smoked salmon safe to eat 2School attendance, refusal skills combat smoking risk in youth 2
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
MOUSE ANTI HUMAN COMPLEMENT SC5B-9...
RABBIT ANTI NEOPTERIN...
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein...
Biology Products: